Vipoglanstat

Star0

DB18126InvestigationalSmall molecule

Vipoglanstat: Overview.

Mechanism: Pharmacologically active on Prostaglandin E synthase
Curator reviewed
Formula / weight: C₃₀H₃₄Cl₂F₅N₅O₃ · 678.53 g/mol (avg)
Also known as: 2-{2,6-Dichloro-3-[(2,2-dimethyl-propionylamino)-methyl]-phenylamino}-6-(2,2-difluoroethoxy)-1-methyl-1H-benzoimidazole-5-carboxylic acid (trans-4-trifluoromethylcyclohexyl)-amide

Resolves to

Compound

UNIIFN57BDR4DACAS1360622-01-0ChEMBLCHEMBL3694493

Structure

InChIKeyPFORUFFGGNOLPJ-QAQDUYKDSA-NSMILESCN1C(NC2=C(Cl)C=CC(CNC(=O)C(C)(C)C)=C2Cl)=NC2=CC(C(=O)N[C@H]3CC[C@@H](CC3)C(F)(F)F)=C(OCC(F)F)C=C12

Targets

O14684PTGES

What you can answer from here — as of September 12, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Vipoglanstat, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account